微生物群
失调
肝硬化
脂肪性肝炎
酒精性肝病
肝病
医学
肠道菌群
酒精性肝炎
脂肪变性
免疫学
疾病
脂肪肝
生物信息学
胃肠病学
内科学
生物
作者
Tannaz Ranjbarian,Bernd Schnabl
出处
期刊:Seminars in Liver Disease
[Georg Thieme Verlag KG]
日期:2023-08-01
卷期号:43 (03): 311-322
被引量:1
摘要
Globally, liver disease caused by alcohol is becoming more prevalent each year. Misuse of alcohol causes a spectrum of liver diseases, such as liver steatosis, steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. The cornerstone of treatment is abstinence from alcohol. In spite of this, available treatment for alcohol-associated liver disease (ALD) shows limited effectiveness currently. There are numerous ways in which alcohol disrupts the gut–liver axis, including dysbiosis of the gut microbiome, disruption of mucus and epithelial cell barriers, impaired production of antimicrobial molecules, and dysfunction of the immune system, causing translocation of viable microbes and microbial products to the liver and systemic circulation. Microbial exposure results in not only inflammation and progression of liver disease but also infections in late-stage ALD. This led scientists to focus their therapeutic strategies and targets for ALD on the gut microbiome. Throughout this review, we address the role of gut microbiome–centered therapeutic approaches for ALD focusing predominantly on randomized controlled trials. We will summarize the latest clinical trials using probiotics, antibiotics, and fecal microbial transplants in modulating the gut–liver axis and for improvement of ALD.
科研通智能强力驱动
Strongly Powered by AbleSci AI